Interactions between HIV-1 Tat and KSHV

Current Topics in Microbiology and Immunology

Volumn 312, Issue , 2007, Pages 309-326

  Aoki, Y ^a   Tosato, G ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; HOST; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS GENE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY;

HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANIMALS; GENE PRODUCTS, TAT; HIV-1; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; SARCOMA, KAPOSI;

EID: 34548653203     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-34344-8_12     Document Type: Review

References (122)

1. Akula SM, Pamod NP, Wang FZ, Chandran B (2002) Integrin a3b1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108:407-419
2. Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A, Paglialunga G, Bussolino F, Noonan D (1996a) HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 12:289-297
3. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG (1994) Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 8:1237-1244
4. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F (1996b) The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 2:1371-1375
5. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, Quinto I, Venuta S, Scala G (1997) HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272:14883-14892
6. Antman K, Chang Y (2000) Kaposi's sarcoma. N Engl J Med 342: 1027-1038
7. Aoki Y, Feldman GM, Tosato G (2003a) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535-1542
8. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G (1999a) Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034-4043
9. Aoki Y, Jones KD, Tosato G (2000a) Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J Hematother Stem Cell Res 9:137-145
10. Aoki Y, Tosato G (1999b) Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 94:4247-4254
11. Aoki Y, Tosato G (2001a) Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk Lymphoma 41:229-237
12. Aoki Y, Tosato G (2004a) HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 104:810-814
13. Aoki Y, Tosato G, Fonville TW, Pittaluga S (2001b) Serum viral interleukin-6 in AIDS-related multicentric Castleman's disease. Blood 97:2526-2527
14. Aoki Y, Tosato G, Nambu Y, Iwamoto A, Yarchoan R (2000b) Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood 95:1109-1110
15. Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G (2000c) Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood 96:1599-1601
16. Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G (2001c) Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 97:2173-2176
17. Ariyoshi K, Schim van der Loeff M, Cook P, Whitby D, Corrah T, Jaffar S, Cham F, Sabally S, O'Donovan D, Weiss RA, Schulz TF, Whittle H (1998) Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol 1:193-199
18. Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E (2000) Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 74:10551-10562
19. Barillari G, Gendelman R, Gallo RC, Ensoli B (1993) The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 90:7941-7945
20. Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S, Crescenzi B, Wolf DG, Schulz TF, Torelli G (2003) Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 9:554-561
21. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602-605
22. Bennasser Y, Bahraoui E (2002) HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-βII and -δ. FASEB J 16:546-554
23. Berkhout B, Gatignol A, Silver J, Jeang KT (1990) Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Nucleic Acids Res 18:1839-1846
24. Bock PJ, Markovitz DM (2001) Infection with HIV-2. AIDS 15 Suppl 5: S35-45
25. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2:373-382
26. Calnan BJ, Biancalana S, Hudson D, Frankel AD (1991) Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev 5:201-210
27. Cannon M, Philpott NJ, Cesarman E (2003) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 77:57-67
28. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA, Haase AT (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-964
29. Cesarman E, Mesri EA, Gershengorn MC (2000) Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med 191:417-422
30. Chang YN, Jeang KT (1992) The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR. Nucleic Acids Res 20:5465-5472
31. Chen LL, Frankel AD, Harder JL, Fawell S, Barsoum J, Pepinsky B (1995) Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. Anal Biochem 227:168-175
32. Chen P, Mayne M, Power C, Nath A (1997) The Tat protein of HIV-1 induces tumor necrosis factor-α production. Implications for HIV-1-associated neurological diseases. J Biol Chem 272:22385-22388
33. Choi J, Means RE, Damania B, Jung JU (2001) Molecular piracy of Kaposi's sarcoma associated herpesvirus. Cytokine Growth Factor Rev 12:245-257
34. Cilla G, Rodes B, Perez-Trallero E, Arrizabalaga J, Soriano V (2001) Molecular evidence of homosexual transmission of HIV type 2 in Spain. AIDS Res Hum Retroviruses 17:417-422
35. Clarke B, Chetty R (2002) Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol 55:19-24
36. Dandekar DH, Ganesh KN, Mitra D (2004) HIV-1 Tat directly binds to NFκB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res 32:1270-1278
37. Delling U, Roy S, Sumner-Smith M, Barnett R, Reid L, Rosen CA, Sonenberg N (1991) The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA. Proc Natl Acad Sci USA 88:6234-6238
38. Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M (1996) Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type 1. J Virol 70:4427-4437
39. Dimitrov DS (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2:109-122
40. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025-1032
41. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412
42. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96:4546-4551
43. Ehret A, Li-Weber M, Frank R, Krammer PH (2001) The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur J Immunol 31:1790-1799
44. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345:84-86
45. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E (1998) Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 394:588-592
46. Frankel AD, Chen L, Cotter RJ, Pabo CO (1988) Dimerization of the tat protein from human immunodeficiency virus: a cysteine-rich peptide mimics the normal metal-linked dimer interface. Proc Natl Acad Sci USA 85:6297-6300
47. Frankel AD, Young JA (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67:1-25
48. Garcia JA, Harrich D, Pearson L, Mitsuyasu R, Gaynor RB (1988) Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 7:3143-3147
49. Gibellini D, Re MC, Vitone F, Rizzo N, Maldini C, La Placa M, Zauli G (2003) Selective up-regulation of functional CXCR4 expression in erythroid cells by HIV-1 Tat protein. Clin Exp Immunol 131:428-435
50. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C (2005) Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105:2510-2518
51. Grundhoff A, Ganem D (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113:124-136
52. Guasparri I, Keller SA, Cesarman E (2004) KSHV vFLIP Is essential for the survival of infected lymphoma cells. J Exp Med 199:993-1003
53. Guo HG, Pati S, Sadowska M, Charurat M, Reitz M (2004) Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol 78:9336-9342
54. Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, Reitz M (2003) Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 77:2631-2639
55. Hauber J, Malim MH, Cullen BR (1989) Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 63:1181-1187
56. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP (1999) Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 189:1545-1554
57. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A (2001) Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 19:3848-3851
58. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezube BJ, Fingeroth JD, Detmar M (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36:683-685
59. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 143:10-14
60. Hyun TS, Subramanian C, Cotter MA, 2nd, Thomas RA, Robertson ES (2001) Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol 75:8761-8771
61. Inoue N, Winter J, Lal RB, Offermann MK, Koyano S (2003) Characterization of entry mechanisms of human herpesvirus 8 by using an Rta-dependent reporter cell line. J Virol 77:8147-8152
62. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G (1999) Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94:2871-2879
63. Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, Siby T, Thior I, Hernandez-Avila M, Sankale JL, et al. (1994) Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343:943-946
64. Karp JE, Pluda JM, Yarchoan R (1996) AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Hematol Oncol Clin North Am 10:1031-1049
65. Katano H, Sato Y, Kurata T, Mori S, Sata T (1999) High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol 155:47-52
66. Katano H, Sato Y, Kurata T, Mori S, Sata T (2000) Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269:335-344
67. Keller SA, Schattner EJ, Cesarman E (2000) Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96:2537-2542
68. Kim TA, Avraham HK, Koh YH, Jiang S, Park IW, Avraham S (2003) HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol 170:2629-2637
69. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, Barton SE (2001) Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 98:3406-3412
70. Klagsbrun M, Baird A (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell 67:229-231
71. Klouche M, Brockmeyer N, Knabbe C, Rose-John S (2002) Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. AIDS 16:F9-18
72. Krown SE (2004) Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 22:399-402
73. Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G (1989) Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 17:3551-3561
74. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S (1997) Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 159:4077-4083
75. Levine AM, Seneviratne L, Espina BM, Wohl AR, Tulpule A, Nathwani BN, Gill PS (2000) Evolving characteristics of AIDS-related lymphoma. Blood 96:4084-4090
76. Li CJ, Wang C, Friedman DJ, Pardee AB (1995) Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92:5461-5464
77. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, et al. (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590
78. Masood R, Cesarman E, Smith DL, Gill PS, Flore O (2002) Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 160:23-29
79. Mitola S, Soldi R, Zanon I, Barra L, Gutierrez MI, Berkhout B, Giacca M, Bussolino F (2000) Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol 74:344-353
80. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000) AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 356:291-296
81. Moore PS, Chang Y (1995) Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl JMed 332:1181-1185
82. Moses AV, Fish KN, Ruhl R, Smith PP, Strussenberg JG, Zhu L, Chandran B, Nelson JA (1999) Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol 73:6892-6902
83. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U (2003) AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 21:2876-2882
84. Oksenhendler E, Cazals-Hatem D, Schulz TF, Barateau V, Grollet L, Sheldon J, Clauvel JP, Sigaux F, Agbalika F (1998) Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N Engl J Med 338:1585-1590
85. Pagtakhan AS, Tong-Starksen SE (1995) Function of exon 2 in optimal trans-activation by Tat of HIV type 2. AIDS Res Hum Retroviruses 11:1367-1372
86. Pagtakhan AS, Tong-Starksen SE (1997) Interactions between Tat of HIV-2 and transcription factor Sp1. Virology 238:221-230
87. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860
88. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, Corey L, Fauci AS (1998) Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 4:341-345
89. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358
90. Poole LJ, Yu Y, Kim PS, Zheng QZ, Pevsner J, Hayward GS (2002) Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 76:3395-3420
91. Popper SJ, Sarr AD, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ (1999) Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 180:1116-1121
92. Prakash O, Teng S, Ali M, Zhu X, Coleman R, Dabdoub RA, Chambers R, Aw TY, Flores SC, Joshi BH (1997) The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice. Arch Biochem Biophys 343:173-180
93. Reeves JD, Doms RW (2002) Human immunodeficiency virus type 2. J Gen Virol 83:1253-1265
94. Rhim H, Rice AP (1993) TAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins. J Virol 67:1110-1121
95. Rhim H, Rice AP (1994) Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA. Nucleic Acids Res 22:4405-4413
96. Rhim H, Rice AP (1995) HIV-1 Tat protein is able to efficiently transactivate the HIV-2 LTR through a TAR RNA element lacking both dinucleotide bulge binding sites. Virology 206:673-678
97. Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N (1990) A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 4:1365-1373
98. Rubartelli A, Poggi A, Sitia R, Zocchi MR (1998) HIV-I Tat: a polypeptide for all seasons. Immunol Today 19:543-545
99. Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA, Rosen CA (1989) Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 63:1-8
100. Rusnati M, Taraboletti G, Urbinati C, Tulipano G, Giuliani R, Molinari-Tosatti MP, Sennino B, Giacca M, Tyagi M, Albini A, Noonan D, Giavazzi R, Presta M (2000) Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB J 14:1917-1930
101. Sakurada S, Katano H, Sata T, Ohkuni H, Watanabe T, Mori S (2001) Effective human herpesvirus 8 infection of human umbilical vein endothelial cells by cell-mediated transmission. J Virol 75:7717-7722
102. Samaniego F, Pati S, Karp JE, Prakash O, Bose D (2001) Human herpesvirus 8 K1-associated nuclear factor-κB-dependent promoter activity: role in Kaposi's sarcoma inflammation? J Natl Cancer Inst Monogr: 15-23
103. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, Dragonetti E, Quinto I, Venuta S (1994) The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 179:961-971
104. Schim van der Loeff MF, Aaby P (1999) Towards a better understanding of the epidemiology of HIV-2. AIDS 13 Suppl A: S69-84
105. Schwarze SR, Hruska KA, Dowdy SF (2000) Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 10:290-295
106. Sommer A, Rifkin DB (1989) Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 138:215-220
107. Spear PG, Longnecker R (2003) Herpesvirus entry: an update. J Virol 77:10179-10185
108. Tao J, Frankel AD (1993) Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins. Proc Natl Acad Sci USA 90:1571-1575
109. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G (1994) Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 269:12456-12461
110. Tomescu C, Law WK, Kedes DH (2003) Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol 77:9669-9684
111. Varthakavi V, Smith RM, Deng H, Sun R, Spearman P (2002) Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology 297:270-280
112. Vieira J, O'Hearn P, Kimball L, Chandran B, Corey L (2001) Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol 75:1378-1386
113. Vives E, Richard JP, Rispal C, Lebleu B (2003) TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci 4:125-132
114. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:687-693
115. Watson K, Edwards RJ (1999) HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem Pharmacol 58:1521-1528
116. Weiss R, Boshoff C (2000) Addressing controversies over Kaposi's sarcoma. J Natl Cancer Inst 92:677-679
117. Westendorp MO, Li-Weber M, Frank RW, Krammer PH (1994) Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 68:4177-4185
118. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA (2000) Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 191:445-454
119. Yao L, Salvucci O, Cardones AR, Hwang ST, Aoki Y, De La Luz Sierra M, Sajewicz A, Pittaluga S, Yarchoan R, Tosato G (2003) Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 102:3900-3905
120. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848
121. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Mazzoni M, Capitani S (1995) The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86:3823-3834
122. Zietz C, Bogner JR, Goebel FD, Lohrs U (1999) An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 340:1923-1924